US EditionShareholder Alert: Robbins LLP Informs Investors of the Alto Neuroscience, Inc. Class Action
NEW YORK, UNITED STATES, JUL 21 – The lawsuit alleges Alto Neuroscience overstated ALTO-100’s effectiveness and prospects, causing investor losses during the IPO through October 2024, according to Rosen Law Firm.
- On Jul 22, 2025, Rosen Law Firm announced a class action on behalf of stock purchasers of Alto Neuroscience, Inc., alleging false statements about ALTO-100's effectiveness and prospects.
- Misstatements overstated clinical and commercial prospects of ALTO-100, which occurred during the Class Period from February 2, 2024, through October 22, 2024.
- The offering documents were negligently prepared and contained untrue statements, causing damages as claimed in the lawsuit.
- Shareholders have until September 19, 2025 to file lead plaintiff motions, and those taking no action can remain absent class members.
- Rosen Law Firm has reclaimed over $1 billion for shareholders, and investors need not actively participate to receive recovery.
Insights by Ground AI
Does this summary seem wrong?
35 Articles
35 Articles
The Courier-Tribune+29 Reposted by 29 other sources
ANRO Investors Have Opportunity to Lead Alto Neuroscience, Inc. Securities Fraud Lawsuit
NEW YORK, July 22, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of Alto Neuroscience, Inc. (NYSE: ANRO): (i) pursuant and/or…
Pomerantz Law Firm Announces the Filing of a Class Action Against Alto Neuroscience, Inc. and Certain Officers
/PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Alto Neuroscience, Inc. ("Alto" or the "Company") (NYSE: ANRO) and...
·United States
Read Full Article
Hastings TribuneReposted by 
Reflector
ReflectorShareholder Alert: Robbins LLP Informs Investors of the Alto Neuroscience, Inc. Class Action
SAN DIEGO, July 21, 2025 (GLOBE NEWSWIRE) -- Robbins LLP informs stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired (a) Alto Neuroscience, Inc. (NYSE: ANRO) common stock pursuant and/or traceable to the…
Coverage Details
Total News Sources35
Leaning Left5Leaning Right3Center10Last UpdatedBias Distribution56% Center
Bias Distribution
- 56% of the sources are Center
56% Center
L 28%
C 56%
R 17%
Factuality
To view factuality data please Upgrade to Premium
